To overcome this challenge, we propose a novel RDAA-positive diagnostic standard, employing three specific antibodies (RNase1, p-ALK Y1604, and p-ALK Y1282/1283) to screen for lung cancer patients with low ALK expression but functional activation by RNase1.Our rigorous protocol ensures a high level of diagnostic accuracy and reliability, which could partially eliminate similar family proteins’ phosphorylation. Here, ALK is linked to lung cancer.